RNPC3 and neoplasm: Most importantly, the non‐invasive administration of ANC@Cas12a RNP caused negligible off‐target side effects (<0.5%) in both U87MG and PDX stem cell GBM xenograft models, which can be mainly ascribed to their stable encapsulation, precise targeting, and on‐demand release of Cas12a/crRNA RNP at the tumor site.